Emboline, a privately held medical technology company focused on reducing stroke and ischemic damage during structural heart procedures, has secured $20 million in growth capital from Trinity Capital. The financing will support the commercialization of the company’s Emboliner Embolic Protection System and further development of its embolic protection technology platform.
Based in Santa Cruz, California, Emboline develops technologies designed to reduce embolic complications during transcatheter cardiovascular procedures, including transcatheter aortic valve replacement (TAVR). The company’s lead product, the Emboliner Embolic Protection System, is designed to capture and remove embolic debris that may be released during structural heart interventions, which could otherwise travel to the brain or other vital organs.
The new funding follows the completion of enrollment in Emboline’s PROTECT H2H investigational device exemption clinical trial, a prospective randomized study evaluating the Emboliner system. Results from the trial are scheduled to be presented in a Late-Breaking Clinical Trial session on March 29, 2026, at the American College of Cardiology Annual Scientific Session in New Orleans.
With the additional capital, Emboline plans to advance preparations for the commercial introduction of the Emboliner system and continue developing additional technologies aimed at reducing embolic risk during structural heart procedures. The company is also preparing regulatory submissions as it targets commercial launches in the United States and Europe later this year.
The Emboliner device is currently investigational and not yet available for commercial sale.
KEY QUOTES
“Emboline’s embolic filtering technology is designed with the goal of giving interventional cardiologists greater confidence when performing complex structural heart procedures while helping reduce the risk of stroke and other embolic complications. We are pleased to support Emboline during this important stage as the company prepares to bring its technology to physicians and patients worldwide.”
Rob Lake, Senior Managing Director Of Life Sciences At Trinity Capital
“We are excited to partner with Trinity Capital at a pivotal moment for Emboline. With the completion of our IDE clinical trial and regulatory submissions ahead, this financing positions us to prepare for commercial launch in the United States and Europe later this year. Our goal is to provide physicians with a comprehensive embolic protection solution that helps reduce stroke and ischemic injury during transcatheter procedures.”
Scott Russell, President And CEO Of Emboline
